Skip to main content
NASDAQ:PRPO

Precipio Stock Forecast, Price & News

$3.82
-0.18 (-4.50 %)
(As of 05/17/2021 09:53 AM ET)
Add
Compare
Today's Range
$3.64
$3.96
50-Day Range
$1.80
$5.25
52-Week Range
$0.65
$9.18
Volume8,176 shs
Average Volume8.96 million shs
Market Capitalization$69.27 million
P/E RatioN/A
Dividend YieldN/A
Beta2.9
30 days | 90 days | 365 days | Advanced Chart
Receive PRPO News and Ratings via Email

Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter.


Precipio logo

About Precipio

Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRPO
CUSIPN/A
Phone(203) 787-7888
Employees54
Year FoundedN/A

Sales & Book Value

Annual Sales$3.13 million
Book Value$1.65 per share

Profitability

Net Income$-13,240,000.00
Net Margins-258.88%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$69.27 million
Next Earnings Date5/17/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.28 out of 5 stars

Medical Sector

870th out of 2,042 stocks

Analytical Instruments Industry

19th out of 29 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Precipio (NASDAQ:PRPO) Frequently Asked Questions

Is Precipio a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precipio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Precipio stock.
View analyst ratings for Precipio
or view top-rated stocks.

What stocks does MarketBeat like better than Precipio?

Wall Street analysts have given Precipio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Precipio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Precipio's next earnings date?

Precipio is scheduled to release its next quarterly earnings announcement on Monday, May 17th 2021.
View our earnings forecast for Precipio
.

How were Precipio's earnings last quarter?

Precipio, Inc. (NASDAQ:PRPO) announced its quarterly earnings data on Thursday, August, 23rd. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $1.93 by $2.08. The biotechnology company earned $0.82 million during the quarter. Precipio had a negative trailing twelve-month return on equity of 98.29% and a negative net margin of 258.88%.
View Precipio's earnings history
.

How has Precipio's stock price been impacted by Coronavirus?

Precipio's stock was trading at $1.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRPO shares have increased by 226.5% and is now trading at $3.82.
View which stocks have been most impacted by COVID-19
.

When did Precipio's stock split? How did Precipio's stock split work?

Shares of Precipio reverse split before market open on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for PRPO?

1 brokerages have issued twelve-month price targets for Precipio's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Precipio's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 83.2% from the stock's current price.
View analysts' price targets for Precipio
or view top-rated stocks among Wall Street analysts.

Who are Precipio's key executives?

Precipio's management team includes the following people:
  • Mr. Ilan Danieli, Founder, Pres, CEO & Director (Age 49, Pay $263.56k)
  • Mr. Carl R. Iberger, CFO & Sec. (Age 68, Pay $210.67k)
  • Mr. Ahmed Zaki Sabet, Chief Operating Officer (Age 34, Pay $173.76k)
  • Ms. Miri Chiko-Radomski, Gen. Counsel
  • Mr. Douglas Sites, VP of Sales
  • Mr. Ayman Mohamed M.D., Sr. VP of R&D and Laboratory Operations (Age 35)
  • Mr. Ori Karev, Chief Strategy Officer

Who are some of Precipio's key competitors?

What other stocks do shareholders of Precipio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Biocept (BIOC), Heat Biologics (HTBX), Portola Pharmaceuticals (PTLA), iBio (IBIO), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Co-Diagnostics (CODX), Inpixon (INPX) and Jaguar Health (JAGX).

What is Precipio's stock symbol?

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

Who are Precipio's major shareholders?

Precipio's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.85%) and Geode Capital Management LLC (0.75%). Company insiders that own Precipio stock include Ahmed Zaki Sabet and Ilan Danieli.
View institutional ownership trends for Precipio
.

Which institutional investors are buying Precipio stock?

PRPO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Geode Capital Management LLC. Company insiders that have bought Precipio stock in the last two years include Ahmed Zaki Sabet, and Ilan Danieli.
View insider buying and selling activity for Precipio
or or view top insider-buying stocks.

How do I buy shares of Precipio?

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precipio's stock price today?

One share of PRPO stock can currently be purchased for approximately $3.82.

How much money does Precipio make?

Precipio has a market capitalization of $69.27 million and generates $3.13 million in revenue each year.

How many employees does Precipio have?

Precipio employs 54 workers across the globe.

What is Precipio's official website?

The official website for Precipio is www.precipiodx.com.

Where are Precipio's headquarters?

Precipio is headquartered at 4 Science Park, New Haven CT, 06511.

How can I contact Precipio?

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at (203) 787-7888 or via email at [email protected]


This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.